Management said it reportedNet Incomefor the third quarter of USD 105.2 million. Revenue of USD 3.4 million consisted of USD 3.3 million of staking revenue, which includes rewards on its treasury and revenue from third party stake, and USD 23,000 of other revenue. Staking …
Net loss was USD 15.5 million for the quarter, against USD 17.5 million in the third quarter of 2025. For the nine months, net loss was USD 70.0 million, against USD 16.0 million, a sharp increase from the prior-year nine-month figure. The accumulatedDeficitwas USD …
Management said revenue came in well ahead of its outlook of just under USD 5 million, primarily reflecting accelerating progress on the 800 kilowatt power module for the Office of Naval Research and the availability of USD 3 million of additional funding under the …
Net loss was USD 7.6 million, or USD 0.05 per share, against a net loss of about USD 5.7 million, or USD 0.11 per share, for the three months ended September 30, 2025. The company's fiscal year ends June 30, so the quarter is …
Management said net revenue reflected increasedDemandfor its pediatric device, a 247% increase from approximately USD 183,000 in the third quarter of 2025. Nine month net revenue more than doubled to USD 1.7 million, which management said puts it in a position to exceed its …
For the nine months, net loss was USD 56.4 million against USD 35.5 million, and loss per share was USD 0.31 against USD 0.40. Cash and cash equivalents were USD 51.7 million at September 30, alongside marketable securities that the filing reports separately. Cash …
The company held USD 276.3 million in cash, cash equivalents and short-term investments at quarter end, compared with USD 283.4 million at the end of the second quarter. Cash burn for the quarter was USD 7.1 million, or about USD 2.4 million per month, …
Gross profit increased USD 239,713 to USD 758,004 from USD 518,291. Cost of revenue rose USD 40,325 to USD 633,831, which the company attributed to directManufacturinglabor costs from added factory hiring in the United Kingdom and higher direct overhead.
Management said it recognized its first pre-commercial product revenue, from its lead cell therapy candidate supplied on a paid per patient basis under a named patient import pathway, in collaboration with two partners and open in multiple countries outside the United States. Management said …
Management said the increase in net loss was primarily driven by a USD 26.9 million non-cash loss on theFair Valueof warrant liabilities, compared with a USD 22.5 million non-cash loss a year earlier. Nine-month net loss was USD 74.9 million against USD 88.7 million.